TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30445841
Drug: Monotherapy (losartan)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (losartan)
Study: 22620494
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI), 300 mg twice daily for 28 days
Study: 18266876
Drug: Implant-supported mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported mandibular overdentures (n=49)
Study: 8612390
Drug: Tacrine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (40 mg) alone
Study: 1597980
Drug: Warm control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm control patients (no drug)
Study: 1597980
Drug: Cold control
Normalized name: Acetaminophen/Diphenhydramine Hydrochloride/Phenylephrine Hydrochloride 650 MG-25 MG-10 MG Oral Tablet [COLD CONTROL PE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold control patients (no drug; n = 20)
Study: 6338768
Drug: Ocular decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular decongestant product 1 (naphazoline hydrochloride + antazoline phosphate)
Study: 6338768
Drug: Ocular decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular decongestant product 2 (naphazoline hydrochloride + pheniramine maleate)
Study: 30136858
Drug: General daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: General daily lifestyle intervention
Study: 26598919
Drug: Kan Jang
Normalized name: ASIAN GINSENG 500 mg in 500 mg ORAL CAPSULE [Cheong-Kwan-Jang Korean HongSam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kan Jang (KJ) oral solution (30 ml/day; 762 mg genuine extracts with standardized contents of 0.2 mg/ml vasicine, 0.8 mg/ml chicoric acid, and 0.03 mg/ml eleutherosides B and E)
Study: 26598919
Drug: Bromhexine hydrochloride
Normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine hydrochloride (24 mg/30 ml/day)
Study: 17080004
Drug: 8 vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 vs. 15 days of antibiotics
Study: 2094341
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms selenium daily for 14 days
Study: 639229
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg/kg intravenously followed by 320 mg orally over 27 hours)
Study: 22773237
Drug: liver suspension
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: liver suspension tape
Study: 22773237
Drug: V‐shaped liver
Approvals — FDA: no, EMA: no, PMDA: no
Description: V‐shaped liver suspension technique (V‐LIST)
Study: 11994337
Drug: 0.27 mg/kg.wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.27 mg/kg.wk of recombinant human GH with low dose ethinyl E2
Study: 11994337
Drug: 0.27 mg/kg.wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.27 mg/kg.wk of recombinant human GH with oral placebo
Study: 11994337
Drug: 0.36 mg/kg.wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.36 mg/kg.wk of recombinant human GH with low dose ethinyl E2
Study: 11994337
Drug: 0.36 mg/kg.wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.36 mg/kg.wk of recombinant human GH with oral placebo
Study: 11994337
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of estrogen (low doses)
Study: 7702820
Drug: Polymyxin B‐neomycin‐hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B‐neomycin‐hydrocortisone drops (single dose intraoperatively)
Study: 31300667
Drug: Micronutrient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient treatment
Study: 27170530
Drug: Condensed regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condensed regimen (100 mg twice daily for 2 weeks followed by 200 mg twice daily)
Study: 27170530
Drug: Conservative regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative regimen (50 mg twice daily for 2 weeks, 100 mg twice daily for 3 weeks, followed by 200 mg twice daily)
Study: 27170530
Drug: High-dose ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ACEI/ARB with condensed regimen
Study: 22813494
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with propofol infusion stopped and remifentanil infusion also stopped during ventilator weaning
Study: 20571327
Drug: Multifactor approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactor approach (cognitive‐behavioral therapies, diet and physical activity counselling, 'on‐off' prescription of orlistat)
Study: 12099782
Drug: Oral pizotifen
Normalized name: pizotifen
DrugBank: Pizotifen (DB06153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pizotifen
Study: 207295
Drug: salbutamol infusion
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol infusion (0.15 microgram kg‐1 min‐1 for 60 min)
Study: 207295
Drug: propranolol injection
Normalized name: propranolol Injection
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propranolol injection (0.3 mg kg‐1 for 10 min); salbutamol infusion
Study: 15704485
Drug: Cerebrolysin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 10 ml
Study: 3147423
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (local anaesthetic)
Study: 9114771
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or Ticlopidine (Control)
Study: 3552176
Drug: Cephalothin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin prophylaxis (25 mg/kg, four doses)
Study: 21992502
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy in addition to GP care
Study: 18492523
Drug: Metformin adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin adherence with lifestyle change
Study: 9408812
Drug: Methylphenidate (5
Normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5 mg plus 20 mg sustained release)
Study: 17947611
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice daily)
Study: 2874782
Drug: Intracapsular extraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracapsular extraction plus Federov implant (Group B)
Study: 12070950
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid restriction at 60% of normal maintenance volumes
Study: 11408131
Drug: Heparin-surface-modified poly(methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified poly(methyl methacrylate) (PMMA) IOL
Study: 20683336
Drug: Monthly Personal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly Personal Digital Assistant supported home assessments by PLWAs with clinic appointments every 3 months
Study: 20683336
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care monthly clinic visits
Study: 18460033
Drug: darunavir 400
Normalized name: darunavir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir 400 mg bid plus ketoconazole 200 mg bid
Study: 18460033
Drug: darunavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 400/100 mg bid plus ketoconazole 200 mg bid
Study: 18460033
Drug: ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole 200 mg bid with darunavir/ritonavir
Study: 15860682
Drug: Added dead
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Added dead space (400 ml)
Study: 15860682
Drug: Added dead
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Added dead space (400 ml) and 38% O2
Study: 12970302
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release melatonin (1.5 mg)
Study: 25759400
Drug: Placebo (matched,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched, with sham titration)
Study: 12101381
Drug: Adjunctive stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive stenting following thrombolytic therapy
Study: 9523907
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution (100% energy carbohydrate)
Study: 7897784
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with trimethoprim/sulfamethoxazole (TMP/SMX) - one tablet twice daily for 3 days followed by 7 days of placebo
Study: 7897784
Drug: 10-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day treatment with trimethoprim/sulfamethoxazole (TMP/SMX) - one tablet twice daily for 10 days
Study: 23941163
Drug: Clinical equipoise
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical equipoise regarding oral anticoagulation
Study: 16939067
Drug: EC-MPS (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-MPS (720 mg b.i.d.)
Study: 11042570
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by one course of perioperative chemotherapy
Study: 9194107
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily)
Study: 9194107
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days
Study: 1355971
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg orally every 12h for 13 doses and intravenous placebo every 8h (n = 5)
Study: 3030039
Drug: Beta 1-selective
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1-selective metoprolol (50 mg b.i.d.)
Study: 3030039
Drug: Non-selective propranolol
Normalized name: Beta blocking agents, non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective propranolol (40 mg b.i.d.)
Study: 31447126
Drug: NTHi vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi vaccine
Study: 21942620
Drug: Oral PHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PHT (combined 17β‐estradiol plus norethisterone)
Study: 21942620
Drug: Oral PHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PHT
Study: 21942620
Drug: Nasal PHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal PHT vs Oral PHT
Study: 31533663
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules (Lactobacillus rhamnosus DSM 14870 and Lactobacillus gasseri DSM 14869) self-administered vaginally once daily for 30 days, then once a week until Day 190.
Study: 31533663
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules self-administered vaginally after antibiotic treatment in Group 2.
Study: 31533663
Drug: Triple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple oral antibiotic combination (cefixime 400 mg stat, doxycycline 100 mg BD for 7 days, metronidazole 2 g stat) in Group 2.
Study: 27449969
Drug: Intrauterine injection
Normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine injection of 1000 IU of hCG before embryo transfer (ET) (n=62)
Study: 27449969
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving an intrauterine injection of physiological saline before ET (n=49)
Study: 27449969
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no intrauterine injection (n=50)
Study: 19878123
Drug: β-blockers (control)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers (control)
Study: 19165383
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1,200 mg)
Study: 11502639
Drug: Oral montelukast,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast, 10 mg qd
Study: 11502639
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol xinafoate powder, 50 microg bid
Study: 9249084
Drug: AGG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGG group (AG + 110 g glucose)
Study: 9249084
Drug: AGF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGF group (AG + 40 g fat)
Study: 8500237
Drug: Hydralazine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (300 mg daily) plus Isosorbide dinitrate (160 mg daily)
Study: 3067246
Drug: Femoxetine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine (600 mg recommended daily dosage, flexible dosing)
Study: 3067246
Drug: Imipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (150 mg recommended daily dosage, flexible dosing)
Study: 31844967
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg hesperidin, twice daily for 12 weeks
Study: 30106248
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) combined with one-session treatment (OST)
Study: 30106248
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) combined with one-session treatment (OST)
Study: 22784013
Drug: naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone 50 mg
Study: 16394687
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups at predicted propofol concentration of 3 microg/ml
Study: 16394687
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups at predicted propofol concentrations of 3 to 7 microg/ml
Study: 3567002
Drug: Leicester Micropalliator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leicester Micropalliator (1 mg h-1 mandatory background infusion + 2 mg i.v. on-demand bolus doses of morphine)
Study: 3567002
Drug: Cardiff Palliator
Normalized name: alligator juniper wood oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiff Palliator (only 2 mg i.v. on-demand bolus doses of morphine)
Study: 30993537
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine (group L)
Study: 27476818
Drug: Corticosteroids (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (prednisolone 15 mg/day)
Study: 23418430
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HT) regimen discontinued for approximately 2 years (Mean = 1.93 years)
Study: 17223424
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) alone
Study: 9385472
Drug: Alpha 1-blockade
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 1-blockade (5 mg prazosin in preceding 24 h)
Study: 3322532
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aspirin (324 mg)
Study: 21942262
Drug: varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline (2 mg/day)
Study: 26704020
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg per day for 3 days)
Study: 12560149
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg per day for 10 days)
Study: 3926254
Drug: 30% fat
Normalized name: Intralipid 30% Fat Emulsion for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% fat parenteral diet
Study: 3926254
Drug: 0% fat
Normalized name: Blended spread - 40% fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% fat parenteral diet
Study: 3926254
Drug: 50% fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% fat parenteral diet
Study: 24658367
Drug: Client-centred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centred therapy
Study: 18341600
Drug: 0.02% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% CHX solution
Study: 15817862
Drug: High-sodium diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium diet (3.86 g/d sodium)
Study: 15817862
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (1.30 g/d sodium)
Study: 16881381
Drug: Reservoir patch
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reservoir patch
Study: 11065040
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches
Study: 11065040
Drug: Transdermal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal treatment
Study: 31679521
Drug: Prolotherapy (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy (4 sessions, monthly intervals)
Study: 31679521
Drug: Physiotherapy (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy (weekly for 4 sessions)
Study: 27220527
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy + Kinesio Taping + Exercise (MT + KT + EX)
Study: 27220527
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy + Manual Therapy + Kinesio Taping + Exercise (HILT + MT + KT + EX)
Study: 24554030
Drug: StomaphyX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: StomaphyX treatment
Study: 22179130
Drug: Pinitol (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinitol (1,200 mg)
Study: 20483969
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy and education (Control)
Study: 11526558
Drug: Morphine mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine mixed with bupivacaine
Study: 11526558
Drug: Control (Sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Sterile saline solution)
Study: 24140390
Drug: Bivalent killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalent killed whole-cell oral cholera vaccine (two doses, 14 days apart)
Study: 19030772
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (at dinnertime)
Study: 19030772
Drug: Neutral protamine
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral protamine Hagedorn (NPH) insulin (at bedtime)
Study: 9118711
Drug: Inhaled cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cocaine base (45 mg)
Study: 9118711
Drug: IV cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV cocaine HCl (0.35 to 0.50 mg/kg)
Study: 9118711
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo (4.5 mg cocaine base)
Study: 9118711
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo (saline solution)
Study: 9118711
Drug: Cocaine (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (inhaled or IV)
Study: 7505979
Drug: Serum PSA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PSA value of 10 ng/mL or less
Study: 2941208
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 12 ml/kg body weight
Study: 2941208
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 18 ml/kg body weight
Study: 20035818
Drug: Silybum marianum
Normalized name: Silybum marianum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybum marianum extract (600 mg/day)
Study: 20035818
Drug: Fluoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (30 mg/day)
Study: 18810506
Drug: Adenosine 5′-triphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 5′-triphosphate (ATP) infusions, maximum of eight weekly intravenous 8-10 h infusions
Study: 16407509
Drug: Aerosol cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol cyclosporine (300 mg, three days a week for two years)
Study: 3327362
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus atropine (0.2 mg kg‐1 plus 0.04 mg kg‐1)
Study: 16517329
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of 3% chloroprocaine
Study: 6475561
Drug: Meglumine, Na‐Ca‐metrizoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine, Na‐Ca‐metrizoate 370 mg I/ml (Isopaque Coronar)
Study: 30468530
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose UVA1 (130 J/cm2)
Study: 29424239
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonists (semaglutide)
Study: 12530280
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (single oral dose)